Ontology highlight
ABSTRACT: Background/aims
To evaluate the cost-effectiveness of ranibizumab as either monotherapy or combined with laser therapy, compared with laser monotherapy, in the treatment of diabetic macular oedema (DME) causing visual impairment from a UK healthcare payer perspective.Methods
A Markov model simulated long-term outcomes and costs of treating DME in one eye (BCVA ≤75 letters) based on data from the RESTORE Phase III trial. Outcomes measured in quality-adjusted life-years (QALYs) were simulated for a 15-year time horizon based on 12-month follow-up from RESTORE and published long-term data. Costs included treatment, disease monitoring, visual impairment and blindness (at 2010 price levels).Results
Ranibizumab monotherapy resulted in a 0.17 QALY gain at an incremental co
SUBMITTER: Mitchell P
PROVIDER: S-EPMC3329632 | biostudies-literature | 2012 May
REPOSITORIES: biostudies-literature